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JPR Highlights 
 
* Ar/modafinil (ar/mod; 200 mg/day) augmentation has been studied in schizophrenia. 
 
* Ar/mod reduces negative symptoms in acutely ill patients. 
 
* Ar/mod does not benefit stable patients with high negative symptom scores. 
 
* Ar/mod does not benefit or worsen positive symptoms, fatigue, or sleepiness. 
 
* Ar/mod is safe and well tolerated in short-term augmentation therapy. 
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ANTIPSYCHOTIC AUGMENTATION WITH MODAFINIL AND ARMODAFINIL 
FOR NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: SYSTEMATIC REVIEW 
AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 
 
 
ABSTRACT 
 
We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) of 
modafinil or armodafinil (ar/mod) augmentation in schizophrenia. We searched PubMed, 
clinical trial registries, reference lists, and other sources for parallel group, placebo-controlled 
RCTs. Our primary outcome variable was the effect of ar/mod on negative symptom 
outcomes. Eight RCTs (pooled N=372; median duration, 8 weeks) met our selection criteria. 
Ar/mod (200 mg/day) significantly attenuated negative symptom ratings (6 RCTs; N=322; 
standardized mean difference [SMD], -0.26; 95% CI, -0.48 to -0.04). This finding remained 
similar in all but one sensitivity analysis -- when the only RCT in acutely ill patients was 
excluded, the outcome was no longer statistically significant (SMD, -0.17; 95% CI, -0.51 to 
0.06). The absolute advantage for ar/mod was small: just 0.27 points on the PANSS-N (6 
RCTs). Ar/mod attenuated total psychopathology ratings (7 RCTs; N=342; SMD, -0.23; 95% 
CI, -0.45 to -0.02) but did not influence positive symptom ratings (5 RCTs; N=302; mean 
difference, -0.58; 95% CI, -1.71 to 0.55). Although data were limited, cognition, fatigue, 
daytime drowsiness, adverse events, and drop out rates did not differ significantly between 
ar/mod and placebo groups. Fixed and random effects models yielded similar results. There 
was no heterogeneity in all but one analysis. Publication bias could not be tested. We 
conclude that ar/mod (200 mg/day) is safe and well tolerated in the short-term treatment of 
schizophrenia. Ar/mod reduces negative symptoms with a small effect size; the absolute 
advantage is also small, and the advantage disappears when chronically ill patients or those 
with high negative symptom burden are treated. Ar/mod does not benefit or worsen other 
symptom dimensions in schizophrenia. 
 
Keywords 
Modafinil 
Armodafinil 
Augmentation 
Schizophrenia 
Negative symptoms 
Positive symptoms 
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Schizophrenia is a major mental illness with a point prevalence of about 0.2-0.7% (Jablensky, 
2009). Whereas the positive symptoms of schizophrenia are reasonably responsive to 
antipsychotic medications, negative and cognitive symptoms tend to persist and are associated 
with considerable functional disability and burden (Tsang et al, 2010; Shamsi et al, 2011). 
Antidepressant (Singh et al, 2010), anticholinergic (Tandon et al, 1992), glutamatergic (Kishi 
and Iwata, 2013), dopaminergic (McKeage and Plosker, 2004), and other treatments (Murphy 
et al, 2006; Hanson et al, 2010; Kishi et al, 2014)) have been studied for efficacy against 
negative symptoms, and these agents have shown varying degrees of promise, usually as 
antipsychotic augmentation agents. Narrative reviews (Lindenmayer et al, 2013; Scoriels et al, 
2013) have reported that negative and cognitive symptoms of schizoprenia improve after 
treatment with psychostimulant drugs; among these, modafinil and armodafinil have 
particularly attracted recent attention. 
 
Modafinil and its R-enantiomer armodafinil (ar/mod) are approved treatments for excessive 
daytime sleepiness associated with narcolepsy, day-night shift work sleep disorder, and 
obstructive sleep apnea (Nishino and Okuro, 2008). However, ar/mod may have efficacy in 
other conditions such as bipolar depression (Sinaert et al, 2013), substance abuse (Mereu et 
al, 2013), and schizophrenia (Lindenmayer et al, 2013), as well. Modafinil increases the 
levels of dopamine, norepinephrine, and serotonin in the prefrontal cortex (de Saint Hilaire et 
al, 2001); dopamine levels are also elevated in the nucleus accumbens (Volkow et al, 2009). 
These actions are mediated through mechanisms such as inhibition of the dopamine 
transporter (Volkow et al, 2009; Federici et al, 2013) and may underlie possible beneficial 
mechanisms of ar/mod in the treatment of negative symptoms and cognitive impairment in 
schizophrenia (Lindenmayer et al, 2013; Scoriels et al, 2013). Benefits in schizophrenia may 
also accrue through actions on glutamate, gamma amino-butyric acid, and orexin systems 
(Minzenberg and Carter, 2008). 
 
Although many small- and moderate-sized randomized controlled trials (RCTs) have 
examined the effects of adjunctive ar/mod on negative and cognitive symptoms of 
schizophrenia, the results have been inconsistent. We therefore conducted a systematic review 
and meta-analysis of RCT data to evaluate the possible benefits and risks of ar/mod 
augmentation for these indications in schizophrenia. 
 
 
METHODS 
We followed recommendations  of the PRISMA statement (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses) including background, search strategy, methods, 
results, discussion and conclusions (Moher et al, 2009). 
 
Objectives 
We sought to ascertain whether ar/mod augmentation of antipsychotic treatment in 
schizophrenia improved negative symptoms and cognitive outcomes without worsening 
positive symptoms and overall psychopathology. We also sought to identify adverse effects 
associated with the ar/mod-antipsychotic combination. The protocol of the study was 
approved in the Department of Psychopharmacology at the National Institute of Mental 
Health and Neurosciences, Bangalore, India. 
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The primary outcome of our study was the effect of adjunctive ar/mod on negative symptoms 
of schizophrenia as assessed by the negative subscale of the Positive and Negative Syndrome 
Scale (PANSS-N) or the Scale for Assessment of Negative Symptoms (SANS). Secondary 
outcomes included effects on PANSS positive symptom subscale scores (PANSS-P), PANSS 
general psychopathology subscale scores (PANSS-GP), PANSS and Brief Psychiatric Rating 
Scale (BPRS) total scores, cognitive measures, and adverse effects with particular reference 
to insomnia. All outcomes were assessed at the study endpoint. 
 
Inclusion and exclusion criteria 
We included all double-blind, parallel group, randomized controlled trials (RCTs) in which 
modafinil or armodafinil at any dose were compared with placebo for at least two weeks in 
patients with schizophrenia. Case reports, case series, open label studies, crossover RCTs, 
and reviews were excluded. Shorter and single-dose studies were also excluded (Figure 1). 
Crossover RCTs were excluded to eliminate carry-over effects on the primary outcome 
variable; in any case, most crossover RCTs were single-dose studies that had cognition as the 
primary outcome. 
 
Search strategy and data extraction 
We used combinations of the terms modafinil, armodafinil, schizophrenia, and psychosis to 
search the following databases of biomedical literature: Medline, PsychINFO, EMBASE,  
ScienceDirect, Google Scholar, CINAHL, Cochrane Database of Systematic Reviews, 
PsychLit, PsycARTICLES, Psychology and Behavioral Sciences Collection, Web of Science, 
OVID, and ProQuest. We also searched the following clinical trials registries: 
ClinicalTrials.gov (United States of America), IFPMA Clinical Trials Portal (International 
Federation of Pharmaceutical Manufacturers & Associations), gsk-clinicalstudyregister.com 
(GlaxoSmithKline), clinicaltrialsregister.eu (European Union), Australian New Zealand 
Clinical Trials Registry (ANZCTR), Chinese Clinical Trials Registry (ChiCTR), Clinical 
Trials Registry India (CTRI), ISRCTN Register, The Netherlands National Trial Register 
(NTR), Sri Lanka Clinical Trials Registry (SLCTR), Canadian Centre for Clinical Trials 
(CCCT), Clinicaltrialresults.org, Food & Drug Administration (FDA), Brazilian Clinical 
Trials Registry (ReBec), Clinical Research Information Service (CRiS) - Republic of Korea, 
Iranian Registry of Clinical Trials (IRCT), Cuban Public Registry of Clinical Trials (RPCEC), 
German Clinical Trials Register (DRKS), Pan-African Clinical Trials Registry (PACTR), and 
the World Health Organization registry (ICTRP). All searches were conducted between 
October 2012 and December 2012. We repeated a search of PubMed in August, 2014. 
Complete details of search strategies, search results, number of search hits obtained for a 
given combination of search terms and relevance of search findings to the research topic are 
available on request. 
 
We inspected titles, abstracts, and/or methods of all papers or clinical trials identified in the 
electronic searches. We obtained the full text of all RCTs and reviews and conducted 
snowball searches of reference lists. We also wrote to authors of all identified RCTs and 
reviews, and to the manufacturers of modafinil in the United States (Cephalon), European 
Union (Teva), Australia and Canada (Shire), and India (Sun Pharmaceuticals, Cipla, and Intas 
Pharmaceuticals) to request for abstracts, posters, and published and unpublished data of 
studies on the use of ar/mod for the treatment of schizophrenia. In case replies were not 
received within seven days, one reminder email was sent.  
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Two reviewers (I.M. and C.A.) independently assessed titles and abstracts and shortlisted 
papers that were possibly appropriate; shortlisting was overinclusive in order to minimize the 
risk of missing relevant studies. These reviewers next examined the full text of all shortlisted 
articles to determine whether they met the predefined study selection criteria. The final set of 
RCTs (Figure 1) were subjected to quality assessment of methodology where we included the 
following criteria from the Jadad scale and the risk of bias assessment tool from the Cochrane 
Collaboration: 1) allocation sequence generation; 2) allocation concealment; 3) blinding of 
participants and personnel; 4) reporting of withdrawals, and 5) reporting of loss to follow-up 
and adverse outcomes. 
 
Data for meta-analysis were extracted by one author (I.M.) and checked for accuracy by other 
authors (S.R., S.K., and C.A.). All concerns or disagreements during all stages of study 
selection, quality assessment, and data extraction were resolved by re-checking source papers, 
by seeking clarification (if necessary) from the authors of selected studies, and by further 
discussion within the study team until full consensus was achieved. 
 
Statistical analysis 
We used Review Manager version 5.2 for Windows, a statistical software package for 
analysing Cochrane Collaboration systematic reviews. We calculated the mean differences for 
continuous data where studies used the same scale for each outcome, and the standardised 
mean difference for data that used different scales (e.g. PANSS-N and SANS). We combined 
final value scores and change from baseline results using mean differences provided the same 
instrument was used (Higgins and Green, 2011).  We did not combine final value and change 
scores in any analysis of standardised mean differences (Higgins and Green, 2011).  
 
We assessed heterogeneity using the I2 statistic, a measure that does not depend on the 
number of studies in the meta-analysis and hence has greater power to detect heterogeneity 
when the number of studies is small. I2  provides an estimate of the percentage of variability 
due to heterogeneity rather than chance alone. An I2 estimate of 50% or greater indicates 
possible heterogeneity, and scores of 75-100% indicate considerable heterogeneity. We used a 
fixed effects model for all outcomes where I2 was <50%, indicating low heterogeneity across 
studies, and a random effects model for all analyses where I2 was >50%.  When we used the 
fixed-effects model, we re-examined results through random effects analysis because tests of 
heterogeneity do not definitely exclude between-study variation. Finally, additional sensitivity 
analyses reexamined outcomes when RCTs that were outlying in certain characteristics (e.g. 
study duration) were excluded. 
 
 
RESULTS 
We found 91 citations of interest in the initial electronic searches, of which 83 were rejected 
for reasons listed in Figure 1. In this figure, 'duplication' refers to trials that were identified in 
registries as well as in electronic databases of published studies. Only 8 studies (Arbabi et al, 
2012; Bobo et al, 2011; Kane et al, 2010; Kane et al, 2012; Pierre et al, 2007; Sevy et al, 
2005; Freudenreich et al, 2009; Lohr et al, 2013) provided data that were relevant to the 
objectives of our review as well as presented in a form that could be extracted for meta-
analysis. One of these RCTs was identified from a clinical trial registry and the manuscript 
was sourced from the authors; the study has now been published (Lohr et al, 2013). 
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The 8 selected RCTs (Table 1) enrolled patients (pooled N=372) who met DSM-IV or DSM-
IV-TR criteria for schizophrenia or schizoaffective disorder. One study recruited patients in 
the active phase of illness (Arbabi et al, 2012); all other studies recruited patients who were 
on a stable dose of antipsychotic medications (for at least the past 4 weeks in 6 RCTs, and 
duration of stable dose not specified in the seventh), and some RCTs additionally required the 
patients to be clinically stable for the previous 2-3 months. Some studies (Sevy et al, 2005; 
Pierre et al, 2007; Bobo et al, 2011; Lohr et al, 2013) reported that patients were also 
receiving other psychotropic agents. Only 3 RCTs specifically recruited patients with a 
minimum severity of negative symptom burden (Pierre et al, 2007; Kane et al, 2012; Lohr et 
al, 2013). 
 
In these 8 RCTs, 187 patients received modafinil (200-300 mg/day) or armodafinil (150-200 
mg/day) and 185 patients received placebo concurrent with their antipsychotic medications. 
Two RCTs (Kane et al, 2010; Kane et al, 2012) examined dose-dependent effects of the study 
drugs; data were therefore extracted only from arms which dosed patients at similar levels 
(200 mg/day) as those in the other 6 RCTs. Study duration was 4-8 weeks (median, 8 weeks) 
in 7 RCTs and 24 weeks in one RCT. 
 
Only two RCTs included in the meta-analysis used clearly described and acceptable sequence 
generation with appropriate double-blinding (Table 2). Only three RCTs clearly described 
adequate blinding. All RCTs adequately reported rates for withdrawal and adverse events, and 
all but one used intent-to-treat analyses. In the one that did not (Sevy et al, 2005), attrition 
was relatively low. As a result, the studies had at least a moderate risk of bias, depending on 
the domain (Table 2). 
 
Negative symptoms of schizophrenia (PANSS-N and SANS total scores combined) 
Data on the primary outcome, that is, the effect of adjunctive ar/mod on negative symptoms 
as assessed by PANSS-N or SANS total, were available for 7 studies (Table 1) (Arbabi et al. 
2012, Bobo et al. 2011, Freudenreich et al. 2009, Kane et al, 2010; Kane et al. 2012, Lohr et 
al. 2013, Pierre et al. 2007). In the last study (Sevy et al. 2005), only the results of the SANS 
subscales were reported and therefore these data could not be included in the meta-analysis. 
We used the fixed-effects model for all but one analysis as there was no evidence of 
significant heterogeneity.  
 
In the primary analysis, there were 322 subjects, 162 on arm/mod and 160 on placebo (Figure 
2). Data from Kane et al (2010) were not included in this analysis because these authors 
presented change scores rather than endpoint ratings. Patients on adjunctive ar/mod had 
significantly lower negative symptoms at treatment endpoint (Standardized Mean Difference 
[SMD], -0.26; 95% CI, -0.48 to -0.04; P=0.02) (Figure 2). Excluding the study with the 24-
week follow-up (Kane et al, 2012) or the 2 studies that reported least square means (Bobo et 
al, 2012; Freudenreich et al, 2009) made little difference to the results (SMDs of -0.37 [95% 
CI, -0.66 to -0.07] and -0.28 [95% CI, -0.54 to -0.02], respectively, both p<0.03). One study 
reported results using both the PANSS-N and SANS (Bobo et al, 2011). Replacing the 
PANSS-N scores with those of the SANS again made no difference to the results (SMD, -
0.24; 95% CI, -0.46 to -0.08; p=0.03).  
 
In all cases, repeating the analyses using the random effects model led to very similar 
outcomes. For instance, the effect of ar/mod on negative symptoms, the primary outcome, 
remained almost the same (SMD, -0.27; 95% CI, -0.50 to -0.04; P=0.02).  
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In an analysis restricted to PANSS-N outcomes (6 RCTs), we included ratings from Kane et 
al (2010) who reported data as change from baseline. This analysis was characterized by 
significant heterogeneity and a random effects model was applied. Patients on adjunctive 
ar/mod had a small but statistically significant advantage over placebo (mean difference, -
0.27; 95% CI, -0.50 to -0.04; P=0.02). We were unable to conduct a meaningful examination 
of SANS scores because of insufficient data for meta-analysis. 
 
The only sensitivity analysis to alter the results was that which excluded Arbabi et al (2012). 
We performed this analysis for two reasons: this was the only study to recruit actively ill 
patients (baseline PANSS total, 114, as opposed to <80 in the remaining studies), and this 
was the only study to report a large and statistically significant separation between modafinil 
and placebo group on the primary outcome measure. Thus, this study was an outlier in these 
two regards. We found that, after the exclusion of Arbabi et al (2012), ar/mod was no longer 
superior to placebo on the primary outcome (SMD, -0.17; 95% CI, -0.51 to 0.06; 
nonsignificant for both fixed and random effect models). 
 
Positive symptoms of schizophrenia (PANSS-P scores) 
Five studies reported on positive symptoms; all used the positive subscale of the PANSS 
(Arbabi et al, 2012; Bobo et al, 2011; Freudenreich et al, 2009; Kane et al, 2012; Lohr et al, 
2013) (Fig 3). There were 302 patients included in this analysis, 152 on ar/mod and 150 on 
placebo (Fig 3). There was no heterogeneity detected, and a fixed effects model was applied. 
Ar/mod augmentation did not significantly influence positive symptom outcomes (mean 
difference, -0.58; 95% CI, -1.71 to 0.55; P=0.31). In sensitivity analyses, the results were 
unchanged when we excluded the study that recruited acutely ill patients (Arbabi et al, 2012), 
the 24-week study (Kane et al, 2012), and the studiesthat reported least-square means (Bobo 
et al, 2011; Freudenreich et al. 2009). The results also remained unchanged when a random 
effects analysis was performed, as well. 
 
Total psychopathology ratings (PANSS and BPRS total scores combined) 
Seven studies reported total psychopathology ratings using the PANSS total score or the 
BPRS total score (Arbabi et al, 2012; Bobo et al, 2011; Freudenreich et al, 2009; Kane et al, 
2012; Lohr et al, 2013; Pierre et al, 2007; Sevy et al, 2007) (Fig 4). There were 342 patients 
included in this analysis, 172 on ar/mod and 170 on placebo. There was no significant 
heterogeneity detected and a fixed effects model was applied. Ar/mod augmentation 
significantly decreased total psychopathology ratings (SMD, -0.23; 95% CI, -0.45 to -0.02; 
P=0.03). In separate sensitivity analyses, the results remained unchanged when the studies 
using least-square means (Bobo et al 2011; Freudenreich et al 2009) were excluded. 
However, the results were no longer significant when the study with the 24-week follow-up 
(Kane et al, 2012) was excluded (SMD, -0.23; 95% CI, -0.51 to 0.05). Similarly in the 
sensitivity analysis in which the only study recruiting acutely ill patients (Arbabi et al, 2012) 
was excluded, ar/mod no longer had a significant effect on total scores (SMD, -0.15; 95% CI, 
-0.38 to 0.08). 
 
Other therapeutic effects 
All studies bar one (Arbabi et al, 2012) assessed cognitive functioning but it was only 
possible to combine data from the two studies (Bobo et al. 2011, Sevy et al. 2005) which used 
the Continuous Performance Test, Identical Pairs version. There were 39 patients in each of 
ar/mod and placebo groups. Fixed- and random-effects models yielded identical results, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
showing no difference in scores between groups (mean difference, -0.14; 95% CI, -0.62 to 
0.34; P=0.57).  
 
Fatigue, as measured using the Fatigue Severity Scale, was reported in two RCTs. There were 
29 and 26 patients, in all, in ar/mod and placebo groups, respectively. There was no 
significant difference in fatigue severity scores between the two groups (random effects 
model, mean difference, -7.12; 95% CI, -16.23 to 1.99). 
 
Daytime drowsiness, as measured using the Epworth Sleepiness Scale, was reported in two 
RCTs. There were 31 and 28 patients, in all, in the ar/mod and placebo groups, respectively. 
There was no significant difference in drowsiness scores between the two groups (random 
effects model, mean difference, -0.78; 95% CI, -3.33 to 1.76). 
 
Adverse events 
In the safety analysis, there were 191 patients randomized to ar/mod and 190 to placebo. Total 
drop out (48 vs 44 patients, respectively) and drop out due to adverse events (22 vs 20 
patients, respectively) did not differ significantly between the two groups. Adverse events that 
were reported in at least two RCTs included dizziness, headache, sexual dysfunction, 
depression, fatigue, and nausea (Table 3). Ar/mod appeared to have been well tolerated with 
no significant differences between treatment and placebo groups (Table 3 and Fig 5). In all 
cases, the fixed and random effects models showed good agreement. 
 
Publication bias 
Publication bias could not be tested because there were too few studies for the various 
outcomes examined.  
 
 
DISCUSSION 
After modafinil administration, dopamine, norepinephrine, and serotonin levels increase in 
the prefrontal cortex (de Saint Hilaire et al, 2001); and dopamine levels increase in the 
nucleus accumbens, as well (Volkow et al, 2009). Modafinil also reduces drowsiness 
(Nishino and Okuro, 2008). We therefore speculated that ar/mod might reduce negative 
symptom burden and improve cognition when used to augment antipsychotic medication in 
schizophrenia. We also sought to assess whether ar/mod augmentation worsens positive 
symptoms. Whereas many RCTs have studied the subject, most were small and therefore 
inconclusive. Ours is the first meta-analysis of the data in the field. 
 
Limitations of the primary studies 
Marder et al (2013) provided guidelines for clinical trials of pharmacological agents that 
target negative symptoms in schizophrenia. All studies met the requirement that recruited 
patients should be below age 65 years. However, studies did not exclude patients with 
depressive symptoms that did not overlap with negative symptoms. No study included data 
from informants. With the exception of the 24-week trial of Kane et al (2012), no study met 
the 12-26 week trial duration requirement for Phase 2 and 3 studies. No study required 
patients to be clinically stable for 4-6 months before recruitment. Finally, no study 
prospectively confirmed stability of positive and negative symptoms for the month preceding 
recruitment. We also note that no study differentiated between primary and secondary 
negative symptoms. 
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Findings and interpretations 
Negative symptoms and cognitive impairment in schizophrenia can be impairing, enduring, 
and difficult to treat (Chue and Lalonde, 2014; Lepage et al, 2014; Millier et al, 2014). If 
ar/mod could attenuate these symptoms, it would be an important therapeutic advance, 
especially as both drugs are generally well tolerated and less likely to be abused than other 
psychostimulants (Mereu et al, 2013). We found that modafinil was associated with a 
significant reduction in negative symptom ratings (6 RCTs; Fig 2); however, the SMD was 
only -0.26, indicating a small effect size. In addition, effect sizes varied considerably across 
studies and in one (Kane et al, 2010), the PANSS-N results were significant whereas the 
SANS results were not. Additionally, when the data were restricted to studies that reported 
PANSS-N outcomes (6 RCTs), the mean difference between ar/mod and placebo was only a 
quarter of a PANSS-N point; this was statistically significant but is clinically of doubtful 
value. Most important of all, when the only study to recruit acutely ill patients (Arbabi et al, 
2012) was excluded, the SMD dropped to -0.17 and was no longer statistically significant. 
We considered excluding Arbabi et al (2012) important because positive symptoms are 
known to contribute to secondary negative symptoms (Buchanan, 2007). Furthermore, 
negative symptom burden assumes clinical significance only after acute psychotic illness is 
controlled; that is, during maintenance therapy, when patients are stable and when they are 
most likely to be considered for negative symptom attenuation treatments.  
 
There are therefore two possible interpretations of our findings. One is that ar/mod has 
limited efficacy in the treatment of negative symptoms. The other is that ar/mod may offer 
advantages if introduced during the acute phase of illness, rather than later. In acute illness, 
ar/mod may attenuate secondary negative symptoms and improve early outcomes. This 
possibility, including the persistence of such benefits and the impact on quality of life, merits 
attention in future studies. 
 
The finding that ar/mod does not improve cognition cannot be considered conclusive because 
it arose from an analysis of the results of just one cognitive measure, which in turn was 
obtained from only two RCTs. The lack of improvement in daytime drowsiness and fatigue is 
similarly inconclusive because each result was obtained from just two RCTs. 
 
A reassuring finding was that ar/mod did not worsen either positive symptoms (5 RCTs; Fig 
3) or total psychopathology ratings (7 RCTs; Fig 4). A limitation of these findings is that 
most of the RCTs were just 4-8 weeks long, and so a duration-dependent increase in the risk 
of relapse, including through the mechanism of an adverse drug interaction (Andrade, 2012), 
would not have been identifiable in the RCTs. We adopt a conservative interpretation of the 
significant reduction in total psychopathology ratings because the benefit was small (SMD, -
0.23), and it was no longer significant in the sensitivity analysis in which the study which 
recruited acutely ill patients (Arbabi et al, 2012) was removed. We suggest that the 
improvement in total scores may have been a consequence of the improvement in negative 
symptom ratings. 
 
It was also reassuring that ar/mod did not worsen insomnia (5 RCTs; Fig 5). A limitation of 
this conclusion is that insomnia was not formally assessed in the RCTs and was mostly 
recorded based on self-report. The same caveat applies to the good tolerability reported 
(Table 3) and for an additional reason, as well - too few RCTs reported individual adverse 
events for confident conclusions to be drawn.  
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Limitations 
The main limitations of our study arose from the nature of the data that we reviewed. Our 
conclusions were based on a grand total of 8 RCTs with a pooled sample size (ar/mod and 
placebo) of only 372 patients and a median sample size of only 33 patients per group. Not all 
studies reported outcomes on all outcome variables of interest, and not all studies reported 
outcomes in a way that permitted data extraction for meta-analysis; for example, one study 
(Kane et al, 2010) reported only change scores and therefore contributed data chiefly to 
adverse effect outcomes (this study reported an advantage for ar/mod on the PANSS-N but 
not on SANS). As a result, sample sizes for important outcomes were further attenuated. 
Adverse event data could be extracted only to the extent that they were actually reported. If an 
adverse event was not mentioned in an RCT, we could not assume that it was absent. 
 
Conclusions 
Modafinil or armodafinil, dosed at approximately 200 mg/day for about 8 weeks, is 
associated with a statistically significant reduction in negative symptom ratings when used as 
an antipsychotic augmentation treatment in schizophrenia. The effect size is small, about a 
quarter of a standard deviation. The absolute advantage is also small, amounting to a quarter 
of a PANSS-N point. These findings suggest that the advantage is of doubtful clinical 
significance. The advantage for ar/mod also disappears when clinically stable, non-acutely ill 
patients are treated (including patients who are specifically recruited for high negative 
symptom burden). Modafinil and armodafinil do not improve or worsen positive symptoms or 
total psychopathology ratings, do not improve cognition, fatigue, or sleepiness, and are 
associated with a placebo level of adverse effects. The data available at present suggest 
possible short-term improvement in negative symptoms with modafinil or armodafinil 
augmentation in acutely ill patients. The data do not encourage the use of these drugs to treat 
negative symptoms in stable schizophrenia patients who have high negative symptom burden 
during maintenance therapy.  
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LEGENDS FOR FIGURES 
 
Figure 1: Identification of randomized, double-blind, placebo-controlled clinical trials for 
inclusion in the systematic review and meta-analysis of the use of modafinil/armodafinil for 
antipsychotic augmentation in schizophrenia. 
 
Figure 2: Negative symptoms of schizophrenia (PANSS Negative subscale scores and SANS 
total scores combined) 
 
 
Figure 3: Positive symptoms of schizophrenia (PANSS Positive subscale scores) 
 
 
Figure 4: Total psychopathology in schizophrenia (PANSS and BPRS total scores) 
 
 
Figure 5: Comparing active and placebo treatments for insomnia 
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Table 1: Characteristics of randomized controlled trials included in the  
meta-analysis  
Author Jadad 
score 
Concurrent antipsychotics, 
dose (mg/day) & sample size 
(n) 
Treatment 
duration 
Drug and 
dose 
N  Age (yrs) 
(mean + SD) 
Males 
(N)  
Arbabi et 
al. 2012 
5 Risperidone 
n = 46 
(6 mg / day) 
 
8 weeks Modafinil 
(200 mg/day) 
23 33.5 + 5.3 18 
Placebo 23 34.1 + 6.3 17 
Bobo et 
al. 2011 
5 Risperidone  n =15 
Clozapine  n=8 
Olanzapine  n=9 
Quetiapine  n=7 
Ziprasidone n= 5 
Aripiprazole  n=8 
Typical neuroleptics  n=6 
(Variable doses) 
6 weeks Armodafinil 
(150 mg/day) 
29 44.0 + 14.6 15 
Placebo 29 38.8 + 11.7 20 
Kane et 
al. 2010 
4 Risperidone 
Olanzapine 
Paliperidone 
(N & doses not given) 
4 weeks Armodafinil 
(200 mg/day) 
15 41.4 + 9.8 11 
Placebo 15 46.0 + 7.8 12 
Kane et 
al. 2012 4 
Risperidone 
Olanzapine 
Paliperidone 
(N & doses not given) 
24 weeks Armodafinil 
(200 mg/day) 
69 43.1 + 11.1 57 
Placebo 70 42.4 + 10.1 46 
Pierre et 
al. 2007 
5 2nd generation anti-psychotics 
n=15 
Clozapine n=3 
Haloperidol n=2 
(doses not specified) 
8 weeks Modafinil 
(median, 200 
mg/day) 
10 49.7 + 6.8 10 
Placebo 10 49.8 + 7.0 9 
Sevy et 
al, 2005 
4 Atypical anti-psychotics (n = 
22) 
Typical anti-psychotics (n = 5) 
(overlapping drugs, doses not 
specified) 
8 weeks Modafinil 
(200 mg/day) 
10 35.9 + 9.4 5 
Placebo 10 38.9 + 10.0 3 
Freuden-
reich et 
al. 2009 
 
4 Clozapine 
(about 370 mg/day) 
8 weeks Modafinil 
(mean, 250 
mg/day) 
19 44.2 + 12.0 15 
Placebo 16 46.4 + 6.4 12 
Lohr et 
al. 2013 
 
4 Risperidone n = 13 
Olanzapine n = 3 
Ziprasidone n = 1 
Quetiapine n = 4 
Aripiprazole n = 3 
Haloperidol n = 2 
Perphenazine n = 2 
Clozapine n = 2 
(variable doses, overlapping 
drugs) 
8 weeks Modafinil (50-
200 mg/day) 
12 47.8 + 13.0 12 
Placebo 12 48.5 + 8.8 12 
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Table 2: Risk of bias assessment of trials of modafinil and armodafinil for 
the treatment of schizophrenia 
 
Study Adequate 
sequence 
generation 
Adequate  
Allocation 
concealment 
Adequate 
blinding of 
personnel 
and 
participants 
Adequate 
reporting 
of 
withdrawals 
and loss to 
follow-up 
Adequate 
reporting 
of serious 
adverse 
events 
Arbabi et 
al. 2012 
Yes  Yes (opaque 
envelopes) 
Yes  Yes  Yes  
Bobo et al. 
2011 
Yes  Yes (off site 
allocation) 
Yes  Yes  Yes 
Kane et al. 
2010 
   Unclear Unclear Unclear Yes  Yes 
Kane et al. 
2012 
   Unclear Unclear Unclear Yes  Yes 
Pierre et 
al. 2007 
   Unclear Unclear Yes Yes  Yes 
Sevy et al. 
2005 
    Unclear  Unclear Unclear Yes Yes 
Freudenreich 
et al. 2009 
Unclear Unclear Unclear Yes Yes 
Lohr et al. 
2013 
Unclear Unclear Unclear Yes Yes 
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Table 3: Adverse effects of ar/modafinil and placebo 
 
Adverse Effect Number 
of 
studies  
Ar/modafinil, 
N (%) 
Placebo, N Results 
Insomnia  5 12/146 (8.2%) 14/146 (9.6%) 0.83 (0.40, 1.74)*  
Dizziness 4  9/86 (10.4%) 7/93 (7.6%) 1.24 (0.49, 3.14)* 
Headache    4  16/126 
(12.7%) 
10/123 (8.1%) 1.50 (0.71, 3.15)* 
Sexual Dysfunction    2  6/52 (11.5%) 7/52 (13.5%) 0.86 (0.31, 2.37)* 
Depression    2  5/48 (11.6%) 6/45 (13.3%) 0.78 (0.24, 2.47)* 
Fatigue    2  5/48 (11.6%) 2/45 (4.4%) 1.71 (0.35, 8.31)** 
Nausea    2  13/92 (14.1%) 7/93 (7.5%) 1.82 (0.77, 4.28)** 
 
* Risk ratio, fixed effect (95% confidence intervals).  
All risk ratios are non-significant. 
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Figure 1: Identification of randomized, double-blind, placebo-controlled clinical trials 
for inclusion in the systematic review and meta-analysis of the use of 
modafinil/armodafinil for antipsychotic augmentation in schizophrenia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: RCT=randomized controlled trial 
Screening of titles, trial protocols, and/or abstracts 
n = 91 
Full-text articles reviewed for 
eligibility 
n = 9 
RCTs included in qualitative synthesis 
n = 8 
RCTs included in meta-analysis 
n = 8 
Excluded, n = 82 
Not in humans, n = 8 
Did not involve schizophrenia or 
modafinil, n = 20 
Review, n = 11 
Not an RCT, n = 15 
Crossover RCT, n = 19 
Duplication, n = 8 
Data not analysed , n = 1 
Excluded, n = 1 
• Same trial with different 
endpoints reported, n = 1 
*Unique titles identified, n = 91 
• Electronic databases, n = 75 (MEDLINE, n = 69; ScienceDirect, n=2; Google Scholar, n = 4)  
• Registry at www.clinicaltrials.gov, n = 12 
• International Clinical Trials Registry Platform, n = 4 
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Figure 2: Negative symptoms of schizophrenia (PANSS Negative subscale 
scores and SANS total scores combined) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Positive symptoms of schizophrenia (PANSS Positive subscale 
scores) 
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Figure 4: Total psychopathology in schizophrenia (PANSS and BPRS total 
scores) 
 
 
 
 
 
 
 
 
 
 
Figure 5: Comparing active and placebo treatments for insomnia 
 
 
 
 
 
 
 
